Drugs / GSK2830930A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01485406 | Dec 2011 → Mar 2012 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01616459 | Jul 2012 → Apr 2013 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2830930A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01616459 ↗ |
| Known as | 12Pn | “received a 3-dose primary vaccination course of GSK2830930A, or 12Pn, vaccine” NCT01616459 ↗ |
| Modality | Vaccine | “Pneumococcal vaccine GSK2830930A” NCT01485406 ↗ |
| Route | Intramuscular | “1 dose administered intramuscularly” NCT01485406 ↗ |